Name

DeFloria

Legal name

DeFloria LLC

Website

https://defloria.bio

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Littleton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Drug Sales: Upon FDA approval of AJA001, DeFloria plans to commercialize the drug through healthcare distribution channels including pharmacy and prescription pathways, with insurance reimbursement capabilities. Charlotte's Web holds exclusive commercial supply rights should AJA001 reach market approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

DeFloria develops AJA001 DeFloria™, an orally delivered, multi-cannabinoid full-spectrum hemp extract (FSHE) botanical drug product derived from the proprietary CW1AS1 hemp cultivar, being advanced through FDA Phase 2 clinical trials for the treatment of irritability associated with Autism Spectrum Disorder (ASD) in adolescents and young adults. The company is a clinical-stage pharmaceutical joint venture and currently has no commercially approved products; revenue is contingent upon successful Phase 2 outcomes, FDA approval, and subsequent commercialization through prescription and insurance channels.

Product overview

DeFloria is a Phase 2 clinical-stage botanical pharmaceutical company developing a single drug candidate, AJA001 oral solution, for the treatment of irritability associated with Autism Spectrum Disorder. The company operates as a focused pharmaceutical developer leveraging proprietary full-spectrum hemp genetics from Charlotte's Web and drug development expertise from Ajna BioSciences, with British American Tobacco as lead investor. AJA001 is the company's sole product pipeline and represents the first systemically absorbed, full-spectrum hemp drug to receive FDA clearance to enter Phase 2 clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

• AJA001 DeFloria™: The lead botanical drug candidate — an oral, multi-cannabinoid full-spectrum hemp extract solution derived from the proprietary CW1AS1 hemp cultivar being developed for autism spectrum disorder irritability. Also referred to as AJA001 oral solution.

Products and services

• AJA001 DeFloria™ (oral cannabinoid botanical drug) An orally delivered, multi-cannabinoid full-spectrum hemp extract (FSHE) botanical drug product containing CBD as the primary cannabinoid plus other active cannabinoids, derived from the proprietary CW1AS1 Cannabis sativa L. hemp cultivar. Being developed through FDA Phase 2 clinical trials for the treatment of irritability associated with Autism Spectrum Disorder (ASD) in adolescents and young adults (ages 13-29), with potential for additional therapeutic applications given multi-mechanism activity.

Quantifiable outcome

• Phase 1 trial demonstrated AJA001 was well-tolerated at doses up to 680mg per day (single dose) and 660mg per day (twice daily)
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Ajna BioSciences PBCcoreStrategic or Co-development Partner · 13 December 2023Ajna BioSciences is a botanical drug development company focused on CNS disorders. As the lead development partner, Ajna provides CMC capabilities, regulatory expertise, and clinical trial management. The company leads regulatory filings, commercialization strategies, and interfaces with DeFloria's experts to guide clinical trial programs. Joel Stanley, CEO of Ajna BioSciences, serves as Board Chairman of DeFloria.
• Charlotte's Web Holdings, Inc.coreStrategic or Co-development Partner · 13 December 2023Charlotte's Web is the market leader in hemp wellness products and provides proprietary hemp genetics, cGMP manufacturing infrastructure worth over $50 million, and decade of cannabinoid research expertise. Charlotte's Web owns approximately one-third of DeFloria and holds exclusive commercial supply rights should AJA001 receive market approval. Co-founders Jared Stanley (CEO) and Joel Stanley (Board Chairman) lead DeFloria's leadership.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Jazz Pharmaceuticals (GW Pharmaceuticals): Jazz acquired GW Pharmaceuticals, developer of Epidiolex — the only FDA-approved CBD drug. DeFloria's Chief Medical Advisor Orrin Devinsky was lead PI for Epidiolex. Directly comparable as a cannabinoid-derived pharmaceutical developer targeting CNS indications via FDA approval.
• Zynerba Pharmaceuticals: Develops transdermal cannabinoid therapeutics for CNS conditions including Fragile X syndrome and autism-related symptoms. Board member Marcel Bonn-Miller has prior Zynerba experience. Closest direct competitor in cannabinoid-based ASD therapeutics.
• Ajna BioSciences PBC: Co-founder of DeFloria and lead development partner providing CMC capabilities and regulatory expertise. Specializes in botanical drug development for CNS disorders — directly comparable as a botanical pharmaceutical development platform.

Others

• Charlotte's Web Holdings: Joint venture partner and ~one-third owner of DeFloria; supplies proprietary CW1AS1 hemp genetics and $50M+ cGMP manufacturing infrastructure. Provides commercial supply rights; comparable as a hemp-derived product company pursuing pharma-grade standards.

Broad incumbents

• Canopy Growth Corporation: Large cannabis company with pharmaceutical-grade cannabinoid R&D capabilities (Marcel Bonn-Miller previously worked there). Broad incumbent pursuing FDA-regulated cannabinoid therapeutics; overlaps with DeFloria's botanical drug strategy at scale.
• Supernus Pharmaceuticals: Specialty CNS pharmaceutical company with approved products for neurology/psychiatry conditions including ADHD and epilepsy. Comparable commercial-stage CNS pharma; benchmarks post-approval commercialization pathway for DeFloria's potential ASD launch.
• Sage Therapeutics (Biogen): Develops CNS therapeutics including Zurzuvae (approved for postpartum depression). Comparable as a CNS-focused biotech that brought novel neuropsychiatric therapies through FDA approval; relevant for ASD commercial pathway benchmarking.

Emerging players

• Axsome Therapeutics: Commercial-stage CNS-focused biotech with FDA-approved therapies for CNS conditions. Comparable as a specialty pharma developing novel CNS therapeutics through rigorous FDA pathways; relevant valuation and regulatory pathway benchmark.
• Compass Pathways: Clinical-stage CNS biotech developing psychedelic-inspired therapies for neuropsychiatric conditions. Comparable as a regulatory-pathway-focused CNS biotech pursuing novel mechanisms of action through FDA trials.
• Esperion Therapeutics: Late-stage clinical biotech with novel therapeutic approach via FDA pathway. Comparable as a small-cap clinical-stage pharma developing a single-platform asset through regulatory milestones; relevant stage-comparable peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/defloria

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DeFloria